Growth hormone responses to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction.

@article{OKeane1994GrowthHR,
  title={Growth hormone responses to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction.},
  author={Veronica O'Keane and Kathryn Abel and Robin MacGregor Murray},
  journal={Biological psychiatry},
  year={1994},
  volume={36 9},
  pages={582-8}
}
The hypothesis that increased central cholinergic neurotransmitter function may be present in schizophrenic illness and may underlie negative symptoms was tested using a neuroendocrine challenge approach. The cholinergic challenge used was the anticholinesterase pyridostigmine, thought to cause the release of growth hormone (GH) from the anterior pituitary by diminishing inhibitory somatostatin tone. Eleven patients, six neuroleptic-naive and five neuroleptic-free, satisfying DSM-III-R criteria… CONTINUE READING